Abstract:e24115 Background: Skin toxicities – one of the most frequent adverse events associated with cancer therapies – can occur with all types of cancer therapeutic interventions. New side effects emerge as new oncology drugs are approved (eg, targeted therapies, immunotherapies), which are associated with a negative impact on quality of life, oncologic treatment dose reductions and/or treatment discontinuation. From a pathophysiologic point of view, skin toxicities during cancer treatment result mostly from alterations in skin barrier function, inflammation, altered immune responses, and phototoxicity. Minimizing alterations in skin barrier function and photoprotection facilitate prevention and management of adverse events to optimize treatment outcomes. Methods: In partnership with the Association Francophone des Soins Oncologiques de Support (AFSOS) and Multinational Association of Supportive Care in Cancer (MASCC), a group of international experts (dermatologists, oncologist, radiation oncologist, oncology nurse) involved in management of cancer patients performed a literature review and a consensus meeting to discuss the role of dermocosmetics to prevent or manage skin adverse events induced by oncology treatments. Dermocosmetics, or cosmeceuticals, include a range of products that can have both therapeutic and cosmetic value. These products help support and maintain the epidermal skin barrier and cutaneous microbiome. Some have been formulated for skin that is fragile, pathological, and sensitive. Results: General recommendations: 1) skin care should be implemented at initiation of therapy for drugs associated with skin toxicities, since prevention is a crucial aspect of management. 2) Skin hydration relieves symptoms and reduces exacerbations of xerosis. 3) Cleansers should have a pH close to 5, while basic and neutral pH cleansers should be avoided. 4) Urea, particularly in the case of some oncology treatments leading to hand foot syndrome, is important due to its exfoliating and hydrating actions. Urea should be avoided with irritated skin. The group also developed recommendations for the management of specific skin toxicities. Conclusions: Emerging evidence is providing support for the beneficial impact of dermocosmetics in management of treatment-related skin toxicities.

Skin and mucosal alterations

The Potential Effect of Oral Microbiota in the Prediction of Mucositis During Radiotherapy for Nasopharyngeal Carcinoma

Approaches to Supportive Care

Prevention and management of radiation-induced dermatitis, mucositis, and xerostomia

Management of Skin Toxicities in Cancer Treatment: An Australian/New Zealand Perspective

Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis

Dermocosmetics in Management of Cancer-Related Skin Toxicities: International Expert Consensus

Recent advances in cancer therapy-associated oral mucositis

Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients

Advances in the understanding and management of mucositis during stem cell transplantation

Emerging evidence on the pathobiology of mucositis

Oral Mucositis: An Update on Innate Immunity and New Interventional Targets

Oral health considerations in cancer survivors

MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

Emerging pharmacotherapy trends in preventing and managing oral mucositis induced by chemoradiotherapy and targeted agents

2091P Dermocosmetics in Management of Cancer-Related Skin Toxicities: International Expert Consensus Highlighting the Key Role of Oncology Nurses

Radiation Induced Mucositis and Its Relationship with Nutritional Status in Head and Neck Cancer Patients Treated with Radiotherapy

[Management of Oral Mucositis in Patients with Head and Neck Cancer Receiving Chemoradiotherapy And/or Molecular Targeted Therapy].

Nursing Procedures for the Prevention and Treatment of Mucositis Induced by Cancer Therapies: Clinical Practice Guideline Based on an Interdisciplinary Consensus Process and a Systematic Literature Search

Prevalence of clinically relevant oral mucositis in outpatients receiving myelosuppressive chemotherapy for solid tumors

Systematic review of basic oral care for the management of oral mucositis in cancer patients